Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst

May 7, 2026 06:40 AM EDTUpdated 08:39 AM DealsPharma An­geli­ni for­ti­fies neu­rol­o­gy port­fo­lio with $4.1B buy­out of Cat­a­lyst Ayisha Sharma News Reporter An­geli­ni Phar­ma is spend­ing $4.1 bil­lion to buy Cat­a­lyst Phar­ma­ceu­ti­cals and its trio of FDA-ap­proved treat­ments for rare neu­ro­log­i­cal dis­eases. The buy­out will add three … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER